ClinicalTrials.gg
CompletedNCT02889796FINCH 1Updated Jun 9, 2021Results posted

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

A Phase 3 interventional study of Filgotinib and Placebo to match filgotinib in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 237 sites in 30 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-09.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,759
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing GLPG0634 in Arthritis, Rheumatoid — 4 open to participants now, 4 under way, none of them phase 3. GLPG0634 · Arthritis, Rheumatoid.

Enrollment
2nd of 17
1,759 · median 287
Started
2016
with 2 others
Phase 3
5 of 17
none open now
Registered
8th of 17
by date
Lead sponsor
5 of 17
Gilead Sciences

Among the 17 studies testing GLPG0634 in Arthritis, Rheumatoid, this one is the 2nd largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 3, and was the 8th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 17 studies testing GLPG0634 in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About GLPG0634

GLPG0634: first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing GLPG0634 in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Have a diagnosis of rheumatoid arthritis (RA) [2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria] , and are ACR functional class I-III.
  • Have ≥ 6 swollen joints (from a swollen joint count based on 66 joints (SJC66)) and ≥ 6 tender joints (from a tender joint count based on 68 joints (TJC68)) at both screening and Day 1.
  • Ongoing treatment with a stable dose of MTX

Key Exclusion Criteria:

  • Previous treatment with any janus kinase (JAK) inhibitor

NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,759 participants (actual)

Study arms

  • Experimental
    Filgotinib 200 mg

    Filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of methotrexate (MTX)

    Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX

  • Experimental
    Filgotinib 100 mg

    Filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX

    Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX

  • Active comparator
    Adalimumab

    Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + adalimumab 40 mg in addition to a stable dose of MTX

    Drug: Placebo to match filgotinib · Drug: Adalimumab · Drug: MTX

  • Experimental
    Placebo to Filgotinib 200 mg

    Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 200 mg to receive filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.

    Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX

  • Experimental
    Placebo to Filgotinib 100 mg

    Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks. After 24 weeks, participants will be rerandomized to filgotinib 100 mg to receive filgotinib 100 mg + placebo to match filgotinib 200 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX.

    Drug: Filgotinib · Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX

  • Placebo comparator
    Placebo Never Received Filgotinib

    Placebo to match filgotinib 200 mg + placebo to match filgotinib 100 mg + placebo to match adalimumab 40 mg in addition to a stable dose of MTX for up to 24 weeks.

    Drug: Placebo to match filgotinib · Drug: Placebo to match adalimumab · Drug: MTX

Interventions

  • 200 mg or 100 mg tablet(s) administered orally once daily

    Also known as: GS-6034

  • DrugPlacebo to match filgotinib

    Tablet(s) administered orally once daily

  • 40 mg administered via subcutaneous injection once every two weeks

  • DrugPlacebo to match adalimumab

    Administered via subcutaneous injection once every two weeks

  • DrugMTX

    Commercially sourced tablet(s) administered orally

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12

    ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity)participant's pain assessment using VAS on a scale of 0-100 (0 and 100 indicating no pain and unbearable pain) health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions,8 components: dressing/ grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. Negative change from baseline indicates improvement (less disability).

    Time frame: Baseline; Week 12

  2. Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 12

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP = hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Week 12

  3. Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24

    Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).

    Time frame: Baseline; Week 24

  4. Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Week 12

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Week 12

  5. Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Week 12

  6. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

    Time frame: Baseline; Week 12

  7. Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 2, 4, 12, and 24

    ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, 12, and 24

  8. Percentage of Participants Who Achieved ACR50 at Weeks 36, and 52

    ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 36, and 52

  9. Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 2, 4, 12, and 24

    ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, 12, and 24

  10. Percentage of Participants Who Achieved ACR70 at Weeks 36, and 52

    ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 36, and 52

  11. Percentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, and 24

    ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, and 24

  12. Percentage of Participants Who Achieved ACR20 Response at Weeks 36, and 52

    ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 36, and 52

  13. Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 2, 4, and 24

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, and 24

  14. Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 36, and 52

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  15. Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 12, and 24

    TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  16. Change From Baseline in Individual ACR Component: TJC68 at Weeks 36, and 52

    TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  17. Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 12, and 24

    The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  18. Change From Baseline in Individual ACR Component: SJC66 at Weeks 36, and 52

    The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  19. Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 2, 4, 12, and 24

    SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  20. Change From Baseline in Individual ACR Component: SGA at Weeks 36, and 52

    SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  21. Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 2, 4, 12, and 24

    PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  22. Change From Baseline in Individual ACR Component: PGA at Weeks 36, and 52

    PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  23. Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 2, 4, 12, and 24

    The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  24. Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 36, and 52

    The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  25. Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 12, and 24

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  26. Change From Baseline in Individual ACR Component: hsCRP at Weeks 36, and 52

    Time frame: Baseline; Weeks 36, and 52

  27. Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, and 24

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, 12, and 24

  28. Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 36, and 52

    The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 36, and 52

  29. Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 12, and 24

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  30. Change From Baseline in DAS28 (CRP) at Weeks 36, and 52

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  31. Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 2, 4, and 24

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, and 24

  32. Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 36, and 52

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 36, and 52

  33. Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 2, 4, and 24

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 2, 4, and 24

  34. Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 36, and 52

    The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

    Time frame: Weeks 36, and 52

  35. American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 2, 4, 12, and 24

    ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.

    Time frame: Weeks 2, 4, 12, and 24

  36. ACR N Percent Improvement (ACR-N) at Weeks 36, and 52

    ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.

    Time frame: Weeks 36, and 52

  37. Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 2, 4, 12, and 24

    Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.

    Time frame: Weeks 2, 4, 12, and 24

  38. Number of Participants With EULAR Response at Weeks 36, and 52

    Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.

    Time frame: Weeks 36, and 52

  39. Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 12, and 24

    CDAI is calculated using formula: CDAI = TJC based on 28 joints (TJC28) + SJC based on 28 joints (SJC28) + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  40. Change From Baseline in CDAI at Weeks 36, and 52

    CDAI is calculated using formula: CDAI = TJC28 + SJC28 + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  41. Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 12, and 24

    SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 2, 4, 12, and 24

  42. Change From Baseline in SDAI at Weeks 36, and 52

    SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  43. Change From Baseline in mTSS at Week 52

    Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).

    Time frame: Baseline; Week 52

  44. Percentage of Participants With no Radiographic Progression From Baseline at Week 24

    Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).

    Time frame: Baseline; Weeks 24

  45. Percentage of Participants With no Radiographic Progression From Baseline at Week 52

    Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).

    Time frame: Baseline; Week 52

  46. 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Weeks 4, 12, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

    Time frame: Weeks 4, 12, and 24

  47. SF-36 PCS Score at Weeks 36, and 52

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

    Time frame: Weeks 36, and 52

  48. Change From Baseline in SF-36 PCS Score at Weeks 4, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Weeks 4, and 24

  49. Change From Baseline in SF-36 PCS Score at Weeks 36, and 52

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Weeks 36, and 52

  50. SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

    Time frame: Weeks 4, 12, and 24

  51. SF-36 MCS Score at Weeks 36, and 52

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

    Time frame: Weeks 36, and 52

  52. Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Weeks 4, 12, and 24

  53. Change From Baseline in SF-36 MCS Score at Weeks 36, and 52

    The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

    Time frame: Baseline; Weeks 36, and 52

  54. Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 4, 12, and 24

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.

    Time frame: Weeks 4, 12, and 24

  55. FACIT-Fatigue Score at Weeks 36, and 52

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.

    Time frame: Weeks 36, and 52

  56. Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

    Time frame: Baseline; Weeks 4, and 24

  57. Change From Baseline in FACIT-Fatigue Score at Weeks 36, and 52

    FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

    Time frame: Baseline; Weeks 36, and 52

  58. Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24

    The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

    Time frame: Weeks 4, 12, and 24

  59. Number of Participants by EQ-5D Health Profile Categories at Weeks 36, and 52

    The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

    Time frame: Weeks 36, and 52

  60. EQ-5D Current Health VAS at Weeks 4, 12, and 24

    EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

    Time frame: Weeks 4, 12, and 24

  61. EQ-5D Current Health VAS at Weeks 36, and 52

    EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

    Time frame: Weeks 36, and 52

  62. Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24

    The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).

    Time frame: Baseline; Weeks 4, 12, and 24

  63. Change From Baseline in EQ-5D Current Health VAS at Weeks 36, and 52

    The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).

    Time frame: Baseline; Weeks 36, and 52

  64. Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  65. WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 36, and 52

  66. WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  67. WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 36, and 52

  68. WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  69. WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 36, and 52

  70. WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 4, 12, and 24

  71. WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.

    Time frame: Weeks 36, and 52

  72. Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  73. Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  74. Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  75. Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  76. Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  77. Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

  78. Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 4, 12, and 24

  79. Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52

    The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

    Time frame: Baseline; Weeks 36, and 52

07

Results

Posted Jan 19, 2021

Participant flow

Participants were enrolled at study sites in Asia, South Africa, Australia, Europe, North America, South America, and New Zealand. The first participant was screened on 30 August 2016. The last study visit occurred on 20 June 2019.

Participant flow — Overall Study
MilestoneFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mgPlacebo Never Received Filgotinib
Started47748032519019196
Completed42442228118118524
Not completed5358449672
Withdrew: Withdrew consent1829201235
Withdrew: Investigator's discretion109103015
Withdrew: Adverse event1788417
Withdrew: Lost to follow-up572026
Withdrew: Protocol violation013004
Withdrew: Non-compliance with study drug020012
Withdrew: Death110101
Withdrew: Pregnancy011000
Withdrew: Randomized but not dosed200002

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in tender joint count based on 68 joints (TJC68), swollen joint count based on 66 joints (SJC66) and in at least 3 of the following 5 items: physician's global assessment of disease activity (PGA) and subject's global assessment of disease activity (SGA) assessed using visual analog scale (VAS) on a scale of 0-100 (0 and 100 indicating no disease activity and maximum disease activity)participant's pain assessment using VAS on a scale of 0-100 (0 and 100 indicating no pain and unbearable pain) health assessment questionnaire-disability index (HAQ-DI) score contains 20 questions,8 components: dressing/ grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 (0 and 3 indicating without difficulty and unable to do); high-sensitivity C-reactive protein (hsCRP). Participants with missing outcomes were set as non-responders.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 1276.6 (72.7 to 80.5)69.8 (65.6 to 74.0)70.5 (65.3 to 75.6)49.9 (45.3 to 54.5)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 26.7 · 95% CI 20.6 to 32.8
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 19.9 · 95% CI 13.6 to 26.2
SecondaryChange From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). When 6 or more categories are non-missing, total possible score is 3. If more than 2 categories are missing, the HAQ-DI score is set to missing. Negative change from baseline indicates improvement (less disability).

Time frame:
Baseline; Week 12
Reported as:
Mean · score on a scale
Change From Baseline in the Health Assessment Questionnaire-Disability Index (HAQ-DI) Score at Week 12
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline1.59 ± 0.6111.55 ± 0.6251.59 ± 0.6001.63 ± 0.613
Change from Baseline at Week 12-0.69 ± 0.613-0.56 ± 0.564-0.61 ± 0.560-0.42 ± 0.544
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Mixed effects model for repeated measure · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.29 · 95% CI -0.36 to -0.22
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.17 · 95% CI -0.24 to -0.10
SecondaryPercentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 12

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP (CRP = hsCRP) for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 12
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Percentage of Participants Who Achieved Disease Activity Score for 28 Joint Count Using C-Reactive Protein [DAS28 (CRP)] < 2.6 at Week 1234.1 (29.7 to 38.5)23.8 (19.8 to 27.7)23.7 (18.9 to 28.5)9.3 (6.6 to 12.0)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 24.8 · 95% CI 19.6 to 30.0
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 14.5 · 95% CI 9.7 to 19.3
  • Filgotinib 200 mg vs Adalimumab · Method proposed by [Liu 2014] · p = <0.001 (P-value of non-inferiority test was calculated from approach proposed by \[Liu 2014\].)
  • Filgotinib 100 mg vs Adalimumab · Method proposed by [Liu 2014] · p = 0.002 (P-value of non-inferiority test was calculated from approach proposed by \[Liu 2014\].)
  • Filgotinib 200 mg vs Adalimumab · Regression, Logistic · p = 0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 10.4 · 95% CI 3.9 to 17.0
  • Filgotinib 100 mg vs Adalimumab · Regression, Logistic · p = 0.99 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 0.1 · 95% CI -6.2 to 6.3
SecondaryChange From Baseline in Modified Total Sharp Score (mTSS) at Week 24

Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).

Time frame:
Baseline; Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Modified Total Sharp Score (mTSS) at Week 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline32.47 ± 47.93936.70 ± 53.06534.82 ± 55.01331.60 ± 53.217
Change from Baseline at Week 240.13 ± 0.9370.17 ± 0.9050.16 ± 0.9480.37 ± 1.417
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.27 · 95% CI -0.43 to -0.12
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.25 · 95% CI -0.40 to -0.10
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Week 12

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Week 12
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Week 1249.7 (45.1 to 54.3)38.8 (34.3 to 43.2)43.4 (37.8 to 48.9)23.4 (19.5 to 27.3)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 26.3 · 95% CI 20.2 to 32.4
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 15.4 · 95% CI 9.4 to 21.4
  • Filgotinib 200 mg vs Adalimumab · Method proposed by [Liu 2014] · p = <0.001 (P-value of non-inferiority test was calculated from approach proposed by \[Liu 2014\].)
  • Filgotinib 100 mg vs Adalimumab · Method proposed by [Liu 2014] · p = 0.054 (P-value of non-inferiority test was calculated from approach proposed by \[Liu 2014\].)
  • Filgotinib 200 mg vs Adalimumab · Regression, Logistic · p = 0.069 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 6.3 · 95% CI -1.0 to 13.6
  • Filgotinib 100 mg vs Adalimumab · Regression, Logistic · p = 0.18 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: -4.6 · 95% CI -11.8 to 2.6
SecondaryChange From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Week 12
Reported as:
Mean · score on a scale
Change From Baseline in 36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Week 12
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline33.4 ± 7.1733.6 ± 7.7532.8 ± 7.7432.9 ± 7.11
Change from Baseline at Week 129.2 ± 8.108.5 ± 7.728.4 ± 7.895.8 ± 7.10
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.7 · 95% CI 2.8 to 4.6
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.1 · 95% CI 2.2 to 4.0
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

Time frame:
Baseline; Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline27.6 ± 10.6827.8 ± 10.6027.2 ± 10.2026.9 ± 10.34
Change from Baseline at Week 129.2 ± 9.829.1 ± 10.158.8 ± 9.196.8 ± 9.89
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.8 · 95% CI 1.7 to 3.9
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.6 · 95% CI 1.5 to 3.7
SecondaryPercentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 2, 4, 12, and 24

ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50% Improvement (ACR50) at Weeks 2, 4, 12, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 29.1 (6.4 to 11.7)5.8 (3.6 to 8.0)6.8 (3.9 to 9.7)1.1 (0.0 to 2.1)
Week 422.3 (18.5 to 26.2)12.9 (9.8 to 16.0)17.2 (13.0 to 21.5)5.9 (3.7 to 8.1)
Week 1247.2 (42.6 to 51.8)36.5 (32.0 to 40.9)35.1 (29.7 to 40.4)19.8 (16.1 to 23.5)
Week 2457.9 (53.3 to 62.4)52.7 (48.1 to 57.3)52.3 (46.7 to 57.9)33.3 (28.9 to 37.6)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 8.0 · 95% CI 5.1 to 10.9
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 4.8 · 95% CI 2.3 to 7.3
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 16.4 · 95% CI 11.9 to 20.9
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 7.0 · 95% CI 3.1 to 10.9
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 27.4 · 95% CI 21.4 to 33.3
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 16.7 · 95% CI 10.9 to 22.5
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 24.6 · 95% CI 18.3 to 31.0
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 19.4 · 95% CI 13.1 to 25.8
SecondaryPercentage of Participants Who Achieved ACR50 at Weeks 36, and 52

ACR50 response is achieved when the participant has: ≥50% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 36, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR50 at Weeks 36, and 52
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3663.2 (58.7 to 67.6)57.7 (53.2 to 62.2)57.5 (52.0 to 63.1)67.9 (61.0 to 74.8)63.4 (56.3 to 70.4)
Week 5264.2 (59.8 to 68.6)60.6 (56.2 to 65.1)62.2 (56.7 to 67.6)68.4 (61.5 to 75.3)66.0 (59.0 to 72.9)
SecondaryPercentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 2, 4, 12, and 24

ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70% Improvement (ACR70) at Weeks 2, 4, 12, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 22.7 (1.2 to 4.3)1.3 (0.2 to 2.3)0.9 (0.0 to 2.1)0.4 (0.0 to 1.1)
Week 49.1 (6.4 to 11.7)3.3 (1.6 to 5.0)3.7 (1.5 to 5.9)1.5 (0.3 to 2.7)
Week 1226.1 (22.1 to 30.2)18.5 (15.0 to 22.1)14.2 (10.2 to 18.1)6.7 (4.4 to 9.1)
Week 2436.2 (31.8 to 40.6)29.6 (25.4 to 33.8)29.5 (24.4 to 34.7)14.9 (11.6 to 18.3)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = 0.008 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 2.3 · 95% CI 0.5 to 4.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.18 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 0.8 · 95% CI -0.5 to 2.2
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 7.6 · 95% CI 4.6 to 10.6
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.067 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 1.9 · 95% CI -0.3 to 4.0
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 19.4 · 95% CI 14.6 to 24.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 11.8 · 95% CI 7.5 to 16.2
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 21.3 · 95.0% CI 15.7 to 26.9
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 14.6 · 95% CI 9.2 to 20.0
SecondaryPercentage of Participants Who Achieved ACR70 at Weeks 36, and 52

ACR70 response is achieved when the participant has: ≥70% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 36, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR70 at Weeks 36, and 52
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3640.2 (35.7 to 44.7)35.4 (31.0 to 39.8)32.9 (27.7 to 38.2)44.7 (37.4 to 52.1)34.6 (27.5 to 41.6)
Week 5244.4 (39.8 to 49.0)39.0 (34.5 to 43.4)41.2 (35.7 to 46.7)48.4 (41.1 to 55.8)37.7 (30.6 to 44.8)
SecondaryPercentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, and 24

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR20 Response at Weeks 2, 4, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 237.3 (32.8 to 41.7)27.5 (23.4 to 31.6)33.5 (28.3 to 38.8)14.9 (11.6 to 18.3)
Week 451.6 (47.0 to 56.2)45.6 (41.1 to 50.2)47.1 (41.5 to 52.7)31.8 (27.5 to 36.1)
Week 2478.1 (74.3 to 81.9)77.7 (73.9 to 81.5)74.5 (69.6 to 79.4)59.2 (54.6 to 63.7)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 22.3 · 95% CI 16.7 to 27.9
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 12.6 · 95% CI 7.2 to 17.9
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 19.8 · 95% CI 13.4 to 26.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 13.8 · 95% CI 7.5 to 20.2
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 18.9 · 95% CI 13.0 to 24.9
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 18.6 · 95% CI 12.6 to 24.5
SecondaryPercentage of Participants Who Achieved ACR20 Response at Weeks 36, and 52

ACR20 response is achieved when the participant has: ≥20% improvement (reduction) from baseline in TJC68, SJC66 and in at least 3 of the following 5 items: PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]; hsCRP. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 36, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR20 Response at Weeks 36, and 52
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3682.9 (79.5 to 86.4)79.2 (75.4 to 82.9)76.3 (71.5 to 81.1)90.5 (86.1 to 95.0)86.9 (81.9 to 92.0)
Week 5282.9 (79.5 to 86.4)79.6 (75.9 to 83.3)77.8 (73.2 to 82.5)86.3 (81.2 to 91.5)85.9 (80.7 to 91.1)
SecondaryChange From Baseline in Individual ACR Component: HAQ-DI at Weeks 2, 4, and 24

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 2, 4, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline1.59 ± 0.6111.55 ± 0.6251.59 ± 0.6001.63 ± 0.613
Change from Baseline at Week 2-0.30 ± 0.443-0.22 ± 0.406-0.29 ± 0.440-0.15 ± 0.357
Change from Baseline at Week 4-0.43 ± 0.493-0.33 ± 0.454-0.40 ± 0.460-0.26 ± 0.431
Change from Baseline at Week 24-0.82 ± 0.632-0.75 ± 0.597-0.78 ± 0.632-0.62 ± 0.598
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.17 · 95% CI -0.22 to -0.12
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.09 · 95% CI -0.14 to -0.04
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.19 · 95% CI -0.24 to -0.13
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.10 · 95% CI -0.15 to -0.04
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.27 · 95% CI -0.34 to -0.19
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.19 · 95% CI -0.26 to -0.11
SecondaryChange From Baseline in Individual ACR Component: HAQ-DI at Weeks 36, and 52

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0 (no disability) to 3 (completely disabled). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: HAQ-DI at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline1.59 ± 0.6111.55 ± 0.6251.59 ± 0.6001.68 ± 0.5781.58 ± 0.603
Change from Baseline at Week 36-0.88 ± 0.633-0.80 ± 0.611-0.81 ± 0.634-0.96 ± 0.637-0.69 ± 0.610
Change from Baseline at Week 52-0.93 ± 0.649-0.85 ± 0.621-0.85 ± 0.647-0.99 ± 0.644-0.73 ± 0.650
SecondaryChange From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 12, and 24

TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · tender joint count
Change From Baseline in Individual ACR Component: Tender Joint Count Based on 68 Joints (TJC68) at Weeks 2, 4, 12, and 24
tender joint countFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline25 ± 13.525 ± 13.424 ± 13.224 ± 13.5
Change from Baseline at Week 2-8 ± 10.1-7 ± 9.3-7 ± 8.8-5 ± 9.0
Change from Baseline at Week 4-11 ± 11.1-10 ± 10.3-9 ± 9.2-8 ± 10.5
Change from Baseline at Week 12-17 ± 11.1-15 ± 10.7-15 ± 9.9-13 ± 11.6
Change from Baseline at Week 24-20 ± 12.1-19 ± 10.9-18 ± 11.1-17 ± 11.7
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3 · 95% CI -4.0 to -2.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.010 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -3.0 to -0.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.0 · 95% CI -5.0 to -2.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -4.0 to -1.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.0 · 95% CI -5.0 to -2.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.0 · 95% CI -4.0 to -1.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.0 · 95% CI -4.0 to -2.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -3.0 to -1.0
SecondaryChange From Baseline in Individual ACR Component: TJC68 at Weeks 36, and 52

TJC was examined on 68 joints of the fingers, elbows, hips, knees, ankles, and toes distal for pain in response to pressure or passive motion at the study time points. Joint pain was scored as 0 = Absent; 1 = Present for each joint. The overall Tender Joint Count ranged from 0 to 68. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · tender joint count
Change From Baseline in Individual ACR Component: TJC68 at Weeks 36, and 52
tender joint countFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline25 ± 13.525 ± 13.424 ± 13.225 ± 12.824 ± 12.9
Change from Baseline at Week 36-21 ± 11.9-20 ± 11.2-19 ± 11.0-21 ± 11.4-19 ± 11.5
Change from Baseline at Week 52-21 ± 12.2-21 ± 11.4-20 ± 11.4-21 ± 11.9-20 ± 11.2
SecondaryChange From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 12, and 24

The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · swollen joint count
Change From Baseline in Individual ACR Component: Swollen Joint Count Based on 66 Joints (SJC66) at Weeks 2, 4, 12, and 24
swollen joint countFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline15 ± 8.515 ± 8.516 ± 8.416 ± 8.5
Change from Baseline at Week 2-6 ± 6.7-5 ± 6.8-6 ± 5.8-5 ± 6.9
Change from Baseline at Week 4-8 ± 7.1-8 ± 7.8-7 ± 6.6-6 ± 7.8
Change from Baseline at Week 12-11 ± 7.5-11 ± 8.1-11 ± 7.1-10 ± 8.4
Change from Baseline at Week 24-13 ± 7.8-13 ± 7.4-13 ± 6.9-12 ± 7.7
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.002 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.0 · 95% CI -2.0 to -0.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.047 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.0 · 95% CI -2.0 to -0.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -3.0 to -1.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -3.0 to -1.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -3.0 to -1.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -2.0 to -1.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -2.0 · 95% CI -3.0 to -1.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.0 · 95.0% CI -2.0 to -1.0
SecondaryChange From Baseline in Individual ACR Component: SJC66 at Weeks 36, and 52

The total SJC66 was based on 66 joints (same 68 joints counted in TJC68 minus hips). It was derived as the sum of all "1s" (presence of a joint swelling was scored as "1" and the absence of swelling was scored as "0," provided the joint was not replaced or could not be assessed due to other reasons) thus collected with no penalty considered for the joints not assessed or those which had been replaced. The range for SJC66 is 0 to 66. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · swollen joint count
Change From Baseline in Individual ACR Component: SJC66 at Weeks 36, and 52
swollen joint countFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline15 ± 8.515 ± 8.516 ± 8.416 ± 8.215 ± 7.9
Change from Baseline at Week 36-14 ± 7.8-13 ± 7.6-14 ± 7.1-14 ± 7.3-13 ± 7.2
Change from Baseline at Week 52-14 ± 8.1-13 ± 7.6-14 ± 7.5-14 ± 7.8-13 ± 7.4
SecondaryChange From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 2, 4, 12, and 24

SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Subject's Global Assessment of Disease Activity (SGA) at Weeks 2, 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline67 ± 19.265 ± 19.767 ± 19.168 ± 18.7
Change from Baseline at Week 2-16 ± 20.1-11 ± 18.4-13 ± 18.1-8 ± 17.2
Change from Baseline at Week 4-22 ± 21.5-16 ± 20.8-19 ± 20.8-13 ± 20.2
Change from Baseline at Week 12-33 ± 24.8-28 ± 24.7-28 ± 23.2-21 ± 24.8
Change from Baseline at Week 24-39 ± 25.8-36 ± 24.9-36 ± 24.9-31 ± 26.9
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.0 · 95% CI -11.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.0 · 95% CI -7.0 to -2.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.0 · 95% CI -12.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.0 · 95% CI -7.0 to -2.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -13.0 · 95% CI -16.0 to -10.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.0 · 95% CI -12.0 to -7.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -11.0 · 95% CI -14.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.0 · 95% CI -11.0 to -5.0
SecondaryChange From Baseline in Individual ACR Component: SGA at Weeks 36, and 52

SGA was assessed by the participant using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: SGA at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline67 ± 19.265 ± 19.767 ± 19.170 ± 17.866 ± 18.7
Change from Baseline at Week 36-42 ± 24.2-39 ± 25.3-39 ± 25.2-45 ± 24.7-38 ± 25.5
Change from Baseline at Week 52-44 ± 24.4-41 ± 25.4-42 ± 25.7-45 ± 27.6-41 ± 25.3
SecondaryChange From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 2, 4, 12, and 24

PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Physician's Global Assessment of Disease Activity (PGA) at Weeks 2, 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline66 ± 16.065 ± 16.567 ± 15.566 ± 16.2
Change from Baseline at Week 2-20 ± 19.3-18 ± 18.5-19 ± 17.9-13 ± 17.8
Change from Baseline at Week 4-28 ± 21.2-26 ± 19.7-26 ± 19.6-20 ± 19.6
Change from Baseline at Week 12-41 ± 20.2-39 ± 20.3-39 ± 20.4-34 ± 22.4
Change from Baseline at Week 24-48 ± 19.2-46 ± 19.6-47 ± 19.4-42 ± 20.4
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.0 · 95% CI -10.0 to -6.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.0 · 95% CI -8.0 to -4.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.0 · 95% CI -11.0 to -6.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.0 · 95% CI -9.0 to -5.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.0 · 95% CI -10.0 to -6.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.0 · 95% CI -10.0 to -5.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.0 · 95% CI -11.0 to -6.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.0 · 95% CI -10.0 to -5.0
SecondaryChange From Baseline in Individual ACR Component: PGA at Weeks 36, and 52

PGA was assessed by the physician using a VAS on a scale of 0 (no disease activity) to 100 (maximum disease activity). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: PGA at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline66 ± 16.065 ± 16.567 ± 15.568 ± 15.664 ± 16.3
Change from Baseline at Week 36-51 ± 19.0-49 ± 19.8-50 ± 18.6-53 ± 19.5-47 ± 20.0
Change from Baseline at Week 52-53 ± 18.2-50 ± 19.2-52 ± 18.9-54 ± 19.7-50 ± 19.3
SecondaryChange From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 2, 4, 12, and 24

The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 2, 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline65 ± 20.464 ± 20.164 ± 19.566 ± 19.0
Change from Baseline at Week 2-16 ± 21.0-12 ± 18.7-13 ± 20.4-7 ± 18.2
Change from Baseline at Week 4-21 ± 23.7-18 ± 20.9-18 ± 21.9-12 ± 20.8
Change from Baseline at Week 12-31 ± 26.9-29 ± 25.3-27 ± 23.6-21 ± 26.0
Change from Baseline at Week 24-38 ± 27.0-37 ± 25.6-35 ± 24.2-30 ± 27.0
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.0 · 95% CI -12.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.0 · 95% CI -8.0 to -3.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.0 · 95% CI -12.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.0 · 95% CI -9.0 to -4.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -12.0 · 95% CI -15.0 to -9.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.0 · 95% CI -13.0 to -7.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -11.0 · 95% CI -14.0 to -7.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.0 · 95% CI -12.0 to -6.0
SecondaryChange From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 36, and 52

The participant assessed their pain severity using a VAS on a scale of 0 (no pain) to 100 (severe pain). A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in Individual ACR Component: Subject's Pain Assessment at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline65 ± 20.464 ± 20.164 ± 19.568 ± 18.065 ± 19.2
Change from Baseline at Week 36-40 ± 26.3-38 ± 26.2-37 ± 25.5-44 ± 24.9-39 ± 25.9
Change from Baseline at Week 52-43 ± 26.2-41 ± 25.9-41 ± 25.6-45 ± 26.6-41 ± 25.6
SecondaryChange From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 12, and 24
Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · mg/L
Change From Baseline in Individual ACR Component: High-Sensitivity C-Reactive Protein (hsCRP) at Weeks 2, 4, 12, and 24
mg/LFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline16.13 ± 21.00516.74 ± 22.98214.56 ± 18.00316.25 ± 24.051
Change from Baseline at Week 2-10.85 ± 20.154-7.67 ± 17.888-8.03 ± 15.594-0.07 ± 17.244
Change from Baseline at Week 4-9.99 ± 21.146-8.44 ± 20.201-7.17 ± 16.896-1.12 ± 19.940
Change from Baseline at Week 12-11.00 ± 18.659-9.55 ± 21.330-7.85 ± 20.632-3.26 ± 22.711
Change from Baseline at Week 24-11.84 ± 20.693-10.54 ± 22.215-6.17 ± 24.224-4.00 ± 19.614
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -10.83 · 95% CI -12.70 to -8.96
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.73 · 95% CI -9.58 to -5.87
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -9.39 · 95% CI -11.33 to -7.45
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.35 · 95% CI -9.29 to -5.42
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -8.02 · 95% CI -9.90 to -6.13
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.46 · 95% CI -8.35 to -4.58
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -7.91 · 95% CI -9.88 to -5.93
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.59 · 95% CI -8.56 to -4.62
SecondaryChange From Baseline in Individual ACR Component: hsCRP at Weeks 36, and 52
Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · mg/L
Change From Baseline in Individual ACR Component: hsCRP at Weeks 36, and 52
mg/LFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline16.13 ± 21.00516.74 ± 22.98214.56 ± 18.00316.54 ± 24.78215.76 ± 21.871
Change from Baseline at Week 36-11.51 ± 21.990-10.72 ± 22.569-8.73 ± 18.214-12.12 ± 23.151-8.50 ± 19.749
Change from Baseline at Week 52-12.19 ± 20.773-11.27 ± 23.129-9.60 ± 16.511-11.43 ± 20.873-8.74 ± 19.921
SecondaryPercentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, and 24

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, 12, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 2, 4, 12, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 252.5 (47.8 to 57.2)46.7 (42.0 to 51.3)51.9 (46.2 to 57.6)40.2 (35.6 to 44.7)
Week 466.2 (61.8 to 70.7)58.0 (53.4 to 62.6)63.9 (58.5 to 69.4)49.9 (45.2 to 54.6)
Week 1278.9 (75.0 to 82.7)71.5 (67.3 to 75.7)72.8 (67.6 to 77.9)57.9 (53.3 to 62.5)
Week 2476.0 (72.0 to 80.0)73.4 (69.3 to 77.6)71.2 (66.1 to 76.4)59.4 (54.8 to 64.0)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 12.3 · 95% CI 5.7 to 18.9
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.043 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 6.5 · 95% CI -0.1 to 13.1
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 16.3 · 95% CI 9.8 to 22.8
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.011 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 8.1 · 95% CI 1.5 to 14.7
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 21.0 · 95% CI 14.9 to 27.0
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 13.6 · 95% CI 7.3 to 19.9
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 16.6 · 95% CI 10.5 to 22.8
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 14.1 · 95% CI 7.8 to 20.3
SecondaryPercentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 36, and 52

The HAQ-DI score is defined as the average of the scores of eight functional categories (dressing and grooming, arising, eating, walking, hygiene, reach, grip, and other activities), usually completed by the participant. Responses in each functional category are collected as 0 (without any difficulty) to 3 (unable to do a task in that area), with or without aids or devices. The eight category scores are averaged into an overall HAQ-DI score on a scale from 0-3 \[0 (no disability) to 3 (completely disabled) when 6 or more categories are non-missing, so total possible score is 3. Improvement is defined as reduction in HAQ-DI, (baseline value - postbaseline value) ≥ 0.22. If more than 2 categories are missing, the HAQ-DI score is set to missing. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 36, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an Improvement (Decrease) in the HAQ-DI Score ≥ 0.22 at Weeks 36, and 52
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3677.1 (73.2 to 81.1)74.9 (70.9 to 79.0)71.5 (66.4 to 76.7)83.2 (77.6 to 88.9)77.7 (71.4 to 83.9)
Week 5275.8 (71.8 to 79.8)73.0 (68.9 to 77.2)70.3 (65.1 to 75.5)81.6 (75.8 to 87.5)71.8 (65.1 to 78.5)
SecondaryChange From Baseline in DAS28 (CRP) at Weeks 2, 4, 12, and 24

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in DAS28 (CRP) at Weeks 2, 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline5.8 ± 0.885.7 ± 0.955.7 ± 0.885.7 ± 0.91
Change from Baseline at Week 2-1.3 ± 1.05-1.0 ± 0.90-1.1 ± 0.90-0.6 ± 0.79
Change from Baseline at Week 4-1.7 ± 1.19-1.4 ± 1.07-1.4 ± 1.04-0.9 ± 0.98
Change from Baseline at Week 12-2.5 ± 1.24-2.2 ± 1.17-2.2 ± 1.12-1.6 ± 1.19
Change from Baseline at Week 24-3.1 ± 1.17-2.8 ± 1.08-2.7 ± 1.20-2.2 ± 1.20
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.7 · 95% CI -0.9 to -0.6
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.4 · 95% CI -0.5 to -0.3
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.8 · 95% CI -0.9 to -0.7
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.5 · 95% CI -0.7 to -0.4
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.0 · 95% CI -1.1 to -0.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.7 · 95% CI -0.8 to -0.5
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -1.0 · 95% CI -1.1 to -0.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.7 · 95% CI -0.8 to -0.5
SecondaryChange From Baseline in DAS28 (CRP) at Weeks 36, and 52

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in DAS28 (CRP) at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline5.8 ± 0.885.7 ± 0.955.7 ± 0.885.9 ± 0.895.6 ± 0.89
Change from Baseline at Week 36-3.2 ± 1.09-2.9 ± 1.17-2.9 ± 1.16-3.3 ± 1.10-2.8 ± 1.08
Change from Baseline at Week 52-3.4 ± 1.11-3.1 ± 1.09-3.1 ± 1.13-3.3 ± 1.16-3.0 ± 1.04
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 2, 4, and 24

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 2, 4, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 213.1 (9.9 to 16.2)8.1 (5.6 to 10.7)9.8 (6.5 to 13.2)3.6 (1.8 to 5.4)
Week 425.5 (21.5 to 29.5)20.4 (16.7 to 24.1)20.9 (16.3 to 25.5)9.3 (6.6 to 12.0)
Week 2460.6 (56.1 to 65.1)53.1 (48.6 to 57.7)50.5 (44.9 to 56.1)33.7 (29.3 to 38.0)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 9.5 · 95% CI 5.8 to 13.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.004 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 4.5 · 95% CI 1.4 to 7.7
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 16.2 · 95% CI 11.3 to 21.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 11.2 · 95% CI 6.5 to 15.8
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 26.9 · 95% CI 20.6 to 33.3
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 19.4 · 95% CI 13.1 to 25.8
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 36, and 52

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 36, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) ≤ 3.2 at Weeks 36, and 52
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3667.4 (63.0 to 71.7)60.2 (55.7 to 64.7)58.2 (52.6 to 63.7)74.7 (68.3 to 81.2)66.5 (59.5 to 73.4)
Week 5268.2 (63.9 to 72.5)62.1 (57.6 to 66.5)61.8 (56.4 to 67.3)69.5 (62.7 to 76.3)67.5 (60.6 to 74.4)
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 2, 4, and 24

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 2, 4, and 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 2, 4, and 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 25.1 (3.0 to 7.1)1.7 (0.4 to 2.9)3.4 (1.3 to 5.5)0.6 (0.0 to 1.4)
Week 413.7 (10.5 to 16.9)8.8 (6.1 to 11.4)8.0 (4.9 to 11.1)2.9 (1.3 to 4.6)
Week 2448.4 (43.8 to 53.0)35.2 (30.8 to 39.6)35.7 (30.3 to 41.1)16.2 (12.8 to 19.6)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 4.4 · 95% CI 2.1 to 6.7
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.17 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 1.0 · 95% CI -0.5 to 2.6
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 10.7 · 95% CI 7.1 to 14.4
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 5.8 · 95% CI 2.6 to 9.0
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 32.2 · 95% CI 26.4 to 38.0
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 19.0 · 95% CI 13.4 to 24.6
  • Filgotinib 200 mg vs Adalimumab · Regression, Logistic · p = <0.001 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: 12.7 · 95% CI 5.6 to 19.9
  • Filgotinib 100 mg vs Adalimumab · Regression, Logistic · p = 0.88 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in response rates: -0.5 · 95% CI -7.5 to 6.5
  • Filgotinib 200 mg vs Adalimumab · Method proposed by [Liu 2014] · p = <0.001 (P-value of non-inferiority test was calculated from approach proposed by \[Liu 2014\].)
  • Filgotinib 100 mg vs Adalimumab · Method proposed by [Liu 2014] · p = <0.001 (P-value of non-inferiority test was calculated from approach proposed by \[Liu 2014\].)
SecondaryPercentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 36, and 52

The DAS28 score is a measure of the participant's disease activity calculated using the tender joint counts (28 joints), swollen joint counts (28 joints), SGA (VAS: 0 = no disease activity to 100 = maximum disease activity), and hsCRP for a total possible score of 1 to 9.4. Higher values indicate higher disease activity. Participants with missing outcomes were set as non-responders.

Time frame:
Weeks 36, and 52
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved DAS28 (CRP) < 2.6 at Weeks 36, and 52
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3650.3 (45.7 to 54.9)42.9 (38.4 to 47.4)42.5 (36.9 to 48.0)52.1 (44.7 to 59.5)46.1 (38.7 to 53.4)
Week 5254.5 (49.9 to 59.1)44.8 (40.2 to 49.3)48.6 (43.0 to 54.2)50.5 (43.2 to 57.9)50.8 (43.4 to 58.1)
SecondaryAmerican College of Rheumatology N Percent Improvement (ACR-N) at Weeks 2, 4, 12, and 24

ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.

Time frame:
Weeks 2, 4, 12, and 24
Reported as:
Mean · percent improvement
American College of Rheumatology N Percent Improvement (ACR-N) at Weeks 2, 4, 12, and 24
percent improvementFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 218.3 ± 19.9814.0 ± 17.1416.3 ± 18.418.0 ± 12.82
Week 427.4 ± 25.2423.0 ± 22.2623.8 ± 22.9415.1 ± 18.92
Week 1246.8 ± 28.4640.6 ± 27.3240.4 ± 26.1828.1 ± 25.22
Week 2458.8 ± 27.7655.4 ± 26.4754.3 ± 28.1342.6 ± 27.73
SecondaryACR N Percent Improvement (ACR-N) at Weeks 36, and 52

ACR-N is defined as the smallest percentage improvement from baseline in swollen joints, tender joints and the median of the following 5 items (PGA, SGA, subject's pain assessment, HAQ-DI and hsCRP). It has a range between 0 and 100%. PGA and SGA assessed using VAS on a scale of 0-100 \[0 and 100 indicating no disease activity and maximum disease activity\]; subject's pain assessment using VAS on a scale of 0-100 \[0 and 100 indicating no pain and unbearable pain\]; HAQ-DI score contains 20 questions,8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities and scored on a scale of 0-3 \[0 and 3 indicating without difficulty and unable to do\]. If this calculation results in a negative value, then the ACR-N is set to 0. The ACR-N value indicates an improvement of N%, with higher numbers indicating greater improvement.

Time frame:
Weeks 36, and 52
Reported as:
Mean · percent improvement
ACR N Percent Improvement (ACR-N) at Weeks 36, and 52
percent improvementFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3662.5 ± 26.0159.1 ± 27.4758.6 ± 27.1763.2 ± 24.5956.1 ± 27.30
Week 5266.0 ± 25.8963.1 ± 26.3463.5 ± 27.0363.8 ± 28.0059.7 ± 26.81
SecondaryNumber of Participants With European League Against Rheumatism (EULAR) Response at Weeks 2, 4, 12, and 24

Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.

Time frame:
Weeks 2, 4, 12, and 24
Reported as:
Count of participants · Participants
Number of Participants With European League Against Rheumatism (EULAR) Response at Weeks 2, 4, 12, and 24
ParticipantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 2 — Good Response58322715
Week 2 — Moderate Response237213158133
Week 2 — No Response157219129313
Week 4 — Good Response117866137
Week 4 — Moderate Response231242156189
Week 4 — No Response115139101228
Week 12 — Good Response234177138106
Week 12 — Moderate Response188225138224
Week 12 — No Response335032101
Week 24 — Good Response284250163154
Week 24 — Moderate Response12415697170
Week 24 — No Response7132144
SecondaryNumber of Participants With EULAR Response at Weeks 36, and 52

Good Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>1.2. Moderate Response: DAS28(CRP) at visit ≤3.2 and improvement from baseline \>0.6 and ≤1.2; DAS28(CRP) at visit \>3.2 and ≤5.1 and improvement from baseline \>0.6; DAS 28(CRP) at visit \>5.1 and improvement from baseline \>1.2. No Response: DAS28(CRP) at visit ≤5.1 and improvement from baseline ≤0.6; DAS 28(CRP) \>5.1 at visit and improvement from baseline ≤1.2.

Time frame:
Weeks 36, and 52
Reported as:
Count of participants · Participants
Number of Participants With EULAR Response at Weeks 36, and 52
ParticipantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 36 — Good Response306276180139124
Week 36 — Moderate Response99126843854
Week 36 — No Response211806
Week 52 — Good Response308282189129126
Week 52 — Moderate Response8298663842
Week 52 — No Response35423
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 12, and 24

CDAI is calculated using formula: CDAI = TJC based on 28 joints (TJC28) + SJC based on 28 joints (SJC28) + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Weeks 2, 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline39.5 ± 11.8538.6 ± 12.2339.2 ± 11.5139.6 ± 11.66
Change from Baseline at Week 2-12.7 ± 11.86-10.7 ± 11.17-11.7 ± 10.06-8.2 ± 10.10
Change from Baseline at Week 4-17.6 ± 12.66-15.6 ± 12.07-15.4 ± 11.13-12.4 ± 11.79
Change from Baseline at Week 12-26.0 ± 12.41-23.3 ± 12.32-23.5 ± 11.43-20.3 ± 13.30
Change from Baseline at Week 24-30.6 ± 11.88-28.6 ± 11.57-28.4 ± 11.45-26.3 ± 12.38
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.6 · 95% CI -5.9 to -3.2
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.0 · 95% CI -4.3 to -1.6
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.2 · 95% CI -6.6 to -3.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.9 · 95% CI -5.3 to -2.4
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.9 · 95% CI -7.3 to -4.6
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.4 · 95% CI -5.8 to -3.1
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.7 · 95% CI -6.9 to -4.5
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.1 · 95% CI -5.3 to -2.9
SecondaryChange From Baseline in CDAI at Weeks 36, and 52

CDAI is calculated using formula: CDAI = TJC28 + SJC28 + SGA + PGA. PGA and SGA are assessed using a VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. CDAI can range from 0 to 76, with higher score indicating more severe disease activity status. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in CDAI at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline39.5 ± 11.8538.6 ± 12.2339.2 ± 11.5141.4 ± 11.0337.8 ± 11.23
Change from Baseline at Week 36-32.1 ± 11.60-29.9 ± 12.18-30.4 ± 11.21-33.8 ± 11.15-29.0 ± 11.02
Change from Baseline at Week 52-32.9 ± 11.69-30.9 ± 11.70-31.6 ± 11.44-34.0 ± 11.20-30.7 ± 10.80
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 12, and 24

SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 2, 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Weeks 2, 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline41.2 ± 12.2640.2 ± 12.7940.6 ± 11.8841.2 ± 12.37
Change from Baseline at Week 2-14.0 ± 12.19-11.4 ± 11.41-12.5 ± 10.52-8.2 ± 10.38
Change from Baseline at Week 4-18.6 ± 13.08-16.4 ± 12.31-16.1 ± 11.47-12.5 ± 12.18
Change from Baseline at Week 12-27.1 ± 12.69-24.1 ± 12.54-24.3 ± 12.03-20.6 ± 13.85
Change from Baseline at Week 24-31.8 ± 12.18-29.7 ± 12.01-29.0 ± 12.19-26.6 ± 12.91
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.7 · 95% CI -7.1 to -4.4
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -3.6 · 95% CI -5.0 to -2.2
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.1 · 95% CI -7.6 to -4.6
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.5 · 95% CI -6.0 to -3.1
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.8 · 95% CI -8.2 to -5.4
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -5.1 · 95% CI -6.5 to -3.7
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -6.5 · 95% CI -7.8 to -5.3
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -4.8 · 95% CI -6.1 to -3.5
SecondaryChange From Baseline in SDAI at Weeks 36, and 52

SDAI is a composite measure that sums the TJC28, SJC28, SGA, PGA, and the hsCRP (in mg/dL). PGA and SGA assessed using VAS on a scale of 0-10 \[0 and 10 indicating no disease activity and maximum disease activity\]. Higher score indicates more severe disease activity status and total possible score is 0 to 86. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in SDAI at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline41.2 ± 12.2640.2 ± 12.7940.6 ± 11.8843.0 ± 11.8139.4 ± 11.81
Change from Baseline at Week 36-33.3 ± 11.92-31.0 ± 12.69-31.2 ± 11.73-35.1 ± 11.83-29.9 ± 11.40
Change from Baseline at Week 52-34.1 ± 12.15-32.0 ± 12.25-32.6 ± 11.99-34.9 ± 11.83-31.6 ± 11.11
SecondaryChange From Baseline in mTSS at Week 52

Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. The mTSS (range \[0-448\]) is defined as the erosion score (range \[0-280\]) plus the joint space narrowing (JSN) score (range \[0-168\]). An erosion score of 0 to 5 is given to each joint in the hands and wrists, and a score of 0 to 10 is given to each joint in the feet where 0 indicates no erosion while 5 or 10 indicates extensive loss of bone (maximum erosion). JSN is scored from 0 to 4, with 0 indicating normal or no narrowing and 4 indicating complete loss of joint space. The maximal TSS is 448. Negative change in value indicates improvement (less erosion of bone, normal joint spaces).

Time frame:
Baseline; Week 52
Reported as:
Mean · score on a scale
Change From Baseline in mTSS at Week 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline32.62 ± 48.30636.24 ± 52.95633.94 ± 53.80326.68 ± 45.87032.38 ± 55.012
Change from Baseline at Week 520.21 ± 1.4340.50 ± 2.0980.58 ± 3.6210.63 ± 2.7820.90 ± 3.152
Statistical analysis
  • Filgotinib 200 mg vs Placebo to Filgotinib 200 mg · MMRM · p = 0.042 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.39 · 95% CI -0.77 to -0.01
  • Filgotinib 100 mg vs Placebo to Filgotinib 100 mg · MMRM · p = 0.039 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: -0.39 · 95% CI -0.77 to -0.02
SecondaryPercentage of Participants With no Radiographic Progression From Baseline at Week 24

Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).

Time frame:
Baseline; Weeks 24
Reported as:
Number · percentage of participants
Percentage of Participants With no Radiographic Progression From Baseline at Week 24
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Change in mTSS ≤ 0.593.8 (91.4 to 96.3)91.1 (88.2 to 94.0)91.9 (88.4 to 95.3)87.2 (83.5 to 90.8)
Change in mTSS ≤ 087.9 (84.6 to 91.2)85.9 (82.4 to 89.4)86.3 (82.1 to 90.6)80.9 (76.7 to 85.2)
Change in mTSS ≤ SDC (1.36)95.8 (93.7 to 97.9)95.0 (92.8 to 97.3)94.5 (91.6 to 97.4)90.3 (87.1 to 93.6)
Statistical analysis
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = 0.002 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in non-progression rate: 6.6 · 95% CI 2.2 to 11.1
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.073 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in non-progression rate: 3.9 · 95% CI -0.8 to 8.6
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = 0.009 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in non-progression rate: 7.0 · 95% CI 1.5 to 12.5
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.061 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in non-progression rate: 5.0 · 95% CI -0.6 to 10.6
  • Filgotinib 200 mg vs Placebo · Regression, Logistic · p = 0.004 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in non-progression rate: 5.5 · 95% CI 1.6 to 9.4
  • Filgotinib 100 mg vs Placebo · Regression, Logistic · p = 0.012 (P-value was calculated from the logistic regression with treatment groups and stratification factors in the model.) · Difference in non-progression rate: 4.7 · 95% CI 0.7 to 8.8
SecondaryPercentage of Participants With no Radiographic Progression From Baseline at Week 52

Participant's radiographs of bilateral hands, wrists and feet are taken and evaluated through central review using the mTSS method. No radiographic progression is defined by the change from baseline in mTSS and is reported for the following categories: Change in mTSS ≤ 0.5, Change in mTSS ≤ 0 and Change in mTSS ≤ smallest detectable change (SDC).

Time frame:
Baseline; Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With no Radiographic Progression From Baseline at Week 52
percentage of participantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Change in mTSS ≤ 0.592.1 (89.4 to 94.8)87.1 (83.7 to 90.5)88.6 (84.7 to 92.6)83.9 (78.2 to 89.5)83.7 (78.0 to 89.4)
Change in mTSS ≤ 087.5 (84.2 to 90.8)81.3 (77.4 to 85.2)82.4 (77.7 to 87.1)73.3 (66.6 to 80.1)77.0 (70.5 to 83.4)
Change in mTSS ≤ SDC (1.83)95.0 (92.7 to 97.2)91.5 (88.7 to 94.3)94.1 (91.2 to 97.1)90.0 (85.3 to 94.7)87.6 (82.5 to 92.8)
Secondary36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Weeks 4, 12, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
36-Item Short Form Survey (SF-36) Physical Component Summary (PCS) Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 439.0 ± 8.2238.2 ± 8.3537.7 ± 8.0736.1 ± 7.40
Week 1242.7 ± 8.3042.1 ± 8.6941.3 ± 8.5738.8 ± 7.83
Week 2443.9 ± 8.4943.7 ± 8.6443.2 ± 8.9540.7 ± 8.10
SecondarySF-36 PCS Score at Weeks 36, and 52

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Time frame:
Weeks 36, and 52
Reported as:
Mean · score on a scale
SF-36 PCS Score at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3645.2 ± 8.2844.4 ± 8.5443.8 ± 8.8445.2 ± 7.9943.2 ± 8.82
Week 5245.6 ± 8.3545.1 ± 8.5745.2 ± 8.5545.1 ± 8.2644.1 ± 8.88
SecondaryChange From Baseline in SF-36 PCS Score at Weeks 4, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Weeks 4, and 24
Reported as:
Mean · score on a scale
Change From Baseline in SF-36 PCS Score at Weeks 4, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline33.4 ± 7.1733.6 ± 7.7532.8 ± 7.7432.9 ± 7.11
Change from Baseline at Week 45.6 ± 6.574.6 ± 6.505.0 ± 6.653.1 ± 6.32
Change from Baseline at Week 2410.4 ± 8.4910.3 ± 8.6410.4 ± 8.477.7 ± 7.97
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.7 · 95% CI 1.9 to 3.4
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.7 · 95% CI 1.0 to 2.5
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.1 · 95% CI 2.1 to 4.1
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.1 · 95% CI 2.0 to 4.1
SecondaryChange From Baseline in SF-36 PCS Score at Weeks 36, and 52

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in SF-36 PCS Score at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline33.4 ± 7.1733.6 ± 7.7532.8 ± 7.7432.2 ± 6.9633.7 ± 6.96
Change from Baseline at Week 3611.6 ± 8.2811.0 ± 8.5311.1 ± 9.0712.9 ± 8.929.5 ± 8.13
Change from Baseline at Week 5212.0 ± 8.7311.5 ± 8.7412.4 ± 9.2113.0 ± 9.5810.4 ± 8.05
SecondarySF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
SF-36 Mental Component Summary (MCS) Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 447.8 ± 9.9047.9 ± 9.6347.9 ± 10.0445.8 ± 10.35
Week 1249.3 ± 9.1449.9 ± 8.9048.9 ± 10.2847.7 ± 10.16
Week 2450.0 ± 8.8250.2 ± 8.9349.3 ± 10.2649.2 ± 9.90
SecondarySF-36 MCS Score at Weeks 36, and 52

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning.

Time frame:
Weeks 36, and 52
Reported as:
Mean · score on a scale
SF-36 MCS Score at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3650.1 ± 8.9651.3 ± 8.8850.7 ± 9.6750.7 ± 9.0450.3 ± 9.47
Week 5250.6 ± 9.3051.5 ± 8.9950.8 ± 9.5150.8 ± 8.5550.1 ± 9.21
SecondaryChange From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in SF-36 MCS Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline43.9 ± 10.4444.6 ± 10.4444.1 ± 10.4443.4 ± 11.01
Change from Baseline at Week 43.9 ± 7.963.4 ± 8.353.7 ± 7.662.3 ± 8.72
Change from Baseline at Week 125.4 ± 9.455.4 ± 8.974.9 ± 9.694.1 ± 9.50
Change from Baseline at Week 246.1 ± 9.235.7 ± 9.575.3 ± 9.255.6 ± 10.28
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.8 · 95% CI 0.9 to 2.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.002 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.5 · 95% CI 0.6 to 2.5
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.006 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.5 · 95% CI 0.4 to 2.5
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 1.7 · 95% CI 0.7 to 2.7
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.086 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 0.9 · 95% CI -0.1 to 2.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.12 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 0.9 · 95% CI -0.2 to 1.9
SecondaryChange From Baseline in SF-36 MCS Score at Weeks 36, and 52

The SF-36 is a 36-item, self-reported, generic, comprehensive, and health-related quality of life questionnaire based on 8 health domains in 2 components: physical well-being (physical functioning, role-physical, bodily pain, general health perceptions), mental well-being (vitality, social functioning, role-emotional, and mental health). Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale with highest possible score of 100. Higher scores indicate better health status or functioning. Positive change in value indicates improvement and better quality of life.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in SF-36 MCS Score at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline43.9 ± 10.4444.6 ± 10.4444.1 ± 10.4443.9 ± 11.0643.4 ± 11.03
Change from Baseline at Week 366.2 ± 10.036.6 ± 10.466.6 ± 9.406.9 ± 12.056.8 ± 9.84
Change from Baseline at Week 526.7 ± 10.536.9 ± 10.616.7 ± 9.907.2 ± 11.316.5 ± 10.35
SecondaryFunctional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 4, 12, and 24

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 433.9 ± 10.3233.3 ± 9.7632.9 ± 10.1130.9 ± 10.43
Week 1236.8 ± 9.6436.7 ± 9.6736.1 ± 9.6833.9 ± 10.32
Week 2438.5 ± 9.1738.5 ± 8.7437.6 ± 9.8235.8 ± 9.94
SecondaryFACIT-Fatigue Score at Weeks 36, and 52

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52.

Time frame:
Weeks 36, and 52
Reported as:
Mean · score on a scale
FACIT-Fatigue Score at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3638.9 ± 8.8439.5 ± 8.7338.6 ± 9.4539.6 ± 8.7837.4 ± 9.88
Week 5239.8 ± 8.6439.8 ± 8.5438.9 ± 9.8739.4 ± 8.7838.0 ± 9.77
SecondaryChange From Baseline in FACIT-Fatigue Score at Weeks 4, and 24

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

Time frame:
Baseline; Weeks 4, and 24
Reported as:
Mean · score on a scale
Change From Baseline in FACIT-Fatigue Score at Weeks 4, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline27.6 ± 10.6827.8 ± 10.6027.2 ± 10.2026.9 ± 10.34
Change from Baseline at Week 46.3 ± 8.595.7 ± 8.775.7 ± 8.473.8 ± 8.76
Change from Baseline at Week 2410.5 ± 10.6310.8 ± 10.7710.3 ± 9.678.4 ± 10.48
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.8 · 95% CI 1.8 to 3.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.2 · 95% CI 1.2 to 3.2
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.6 · 95% CI 1.5 to 3.8
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.8 · 95% CI 1.6 to 3.9
SecondaryChange From Baseline in FACIT-Fatigue Score at Weeks 36, and 52

FACIT-Fatigue scale is a brief, 13-item, symptom-specific questionnaire that specifically assesses the self-reported severity of fatigue and its impact upon daily activities and functioning in the past 7 days. The FACIT-Fatigue uses 0 (not at all) to 4 (very much) numeric rating scales for a total possible score of 0 to 52. Positive change in value indicates improvement (no or less severity of fatigue).

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in FACIT-Fatigue Score at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline27.6 ± 10.6827.8 ± 10.6027.2 ± 10.2026.8 ± 10.1327.9 ± 10.56
Change from Baseline at Week 3611.0 ± 10.2211.7 ± 10.9011.3 ± 10.1812.8 ± 10.769.5 ± 10.25
Change from Baseline at Week 5211.9 ± 10.2112.2 ± 10.8811.7 ± 10.7912.9 ± 11.5510.1 ± 10.06
SecondaryNumber of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24

The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Time frame:
Weeks 4, 12, and 24
Reported as:
Count of participants · Participants
Number of Participants by European Quality of Life 5 Dimensions (EQ-5D) Health Profile Categories at Weeks 4, 12, and 24
ParticipantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Mobility: Week 4 — No Problems13012984100
Mobility: Week 4 — Slight Problems176173107149
Mobility: Week 4 — Moderate Problems11312296150
Mobility: Week 4 — Severe Problems44463156
Mobility: Week 4 — Extreme Problems5112
Mobility: Week 12 — No Problems178177116132
Mobility: Week 12 — Slight Problems153151103154
Mobility: Week 12 — Moderate Problems999767112
Mobility: Week 12 — Severe Problems21312138
Mobility: Week 12 — Extreme Problems4101
Mobility: week 24 — No Problems182189117131
Mobility: week 24 — Slight Problems14213690126
Mobility: week 24 — Moderate Problems68755789
Mobility: week 24 — Severe Problems19171224
Mobility: week 24 — Extreme Problems5212
Self-care: Week 4 — No Problems177163111138
Self-care: Week 4 — Slight Problems180183120164
Self-care: Week 4 — Moderate Problems8610374124
Self-care: Week 4 — Severe Problems23201325
Self-care: Week 4 — Extreme Problems2216
Self-care: Week 12 — No Problems243222147165
Self-care: Week 12 — Slight Problems149150102159
Self-care: Week 12 — Moderate Problems53744988
Self-care: Week 12 — Severe Problems89921
Self-care: Week 12 — Extreme Problems2204
Self-care: Week 24 — No Problems255249157164
Self-care: Week 24 — Slight Problems10912175140
Self-care: Week 24 — Moderate Problems45393654
Self-care: Week 24 — Severe Problems48714
Self-care: Week 24 — Extreme Problems3220
Usual Activities: Week 4 — No Problems1101026965
Usual Activities: Week 4 — Slight Problems203193133195
Usual Activities: Week 4 — Moderate Problems11114290143
Usual Activities: Week 4 — Severe Problems38332552
Usual Activities: Week 4 — Extreme Problems6122
Usual Activities: Week 12 — No Problems15714997103
Usual Activities: Week 12 — Slight Problems200191130184
Usual Activities: Week 12 — Moderate Problems809067116
Usual Activities: Week 12 — Severe Problems16231332
Usual Activities: Week 12 — Extreme Problems2402
Usual Activities: Week 24 — No Problems184175109107
Usual Activities: Week 24 — Slight Problems164171105163
Usual Activities: Week 24 — Moderate Problems54635286
Usual Activities: Week 24 — Severe Problems139915
Usual Activities: Week 24 — Extreme Problems1121
Pain/Discomfort: Week 4 — No Problems42382614
Pain/Discomfort: Week 4 — Slight Problems215185118157
Pain/Discomfort: Week 4 — Moderate Problems154204127198
Pain/Discomfort: Week 4 — Severe Problems51414780
Pain/Discomfort: Week 4 — Extreme Problems6318
Pain/Discomfort: Week 12 — No Problems58713429
Pain/Discomfort: Week 12 — Slight Problems260217145200
Pain/Discomfort: Week 12 — Moderate Problems117150106154
Pain/Discomfort: Week 12 — Severe Problems20172251
Pain/Discomfort: Week 12 — Extreme Problems0203
Pain/Discomfort: Week 24 — No Problems82785639
Pain/Discomfort: Week 24 — Slight Problems226224127196
Pain/Discomfort: Week 24 — Moderate Problems8610382110
Pain/Discomfort: Week 24 — Severe Problems21131227
Pain/Discomfort: Week 24 — Extreme Problems1100
Anxiety/Depression: Week 4 — No Problems211224151196
Anxiety/Depression: Week 4 — Slight Problems163158111149
Anxiety/Depression: Week 4 — Moderate Problems72814486
Anxiety/Depression: Week 4 — Severe Problems2181325
Anxiety/Depression: Week 4 — Extreme Problems1001
Anxiety/Depression: Week 12 — No Problems235246152216
Anxiety/Depression: Week 12 — Slight Problems154143106137
Anxiety/Depression: Week 12 — Moderate Problems54634462
Anxiety/Depression: Week 12 — Severe Problems125419
Anxiety/Depression: Week 12 — Extreme Problems0013
Anxiety/Depression: Week 24 — No Problems230256160204
Anxiety/Depression: Week 24 — Slight Problems13611975120
Anxiety/Depression: Week 24 — Moderate Problems42373339
Anxiety/Depression: Week 24 — Severe Problems8568
Anxiety/Depression: Week 24 — Extreme Problems0231
SecondaryNumber of Participants by EQ-5D Health Profile Categories at Weeks 36, and 52

The EQ-5D-5 levels (EQ-5D-5L) is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. EQ-5D-5L consists of 2 components: a descriptive system of the participant's health and a rating of his or her current health state on a 0-100 VAS. The descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. Rating gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Time frame:
Weeks 36, and 52
Reported as:
Count of participants · Participants
Number of Participants by EQ-5D Health Profile Categories at Weeks 36, and 52
ParticipantsFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Mobility: Week 36 — No Problems2021891228678
Mobility: Week 36 — Slight Problems121136825867
Mobility: Week 36 — Moderate Problems5864482628
Mobility: Week 36 — Severe Problems131516711
Mobility: Week 36 — Extreme Problems11200
Mobility: Week 52 — No Problems1971871308277
Mobility: Week 52 — Slight Problems117115794761
Mobility: Week 52 — Moderate Problems5758383427
Mobility: Week 52 — Severe Problems11191038
Mobility: Week 52 — Extreme Problems40011
Self-care: Week 36 — No Problems254249164114108
Self-care: Week 36 — Slight Problems104113674546
Self-care: Week 36 — Moderate Problems3136301725
Self-care: Week 36 — Severe Problems55615
Self-care: Week 36 — Extreme Problems12300
Self-care: Week 52 — No Problems251245159105101
Self-care: Week 52 — Slight Problems98102724448
Self-care: Week 52 — Moderate Problems3025241618
Self-care: Week 52 — Severe Problems56216
Self-care: Week 52 — Extreme Problems21011
Usual Activities: Week 36 — No Problems1761721258272
Usual Activities: Week 36 — Slight Problems160171907170
Usual Activities: Week 36 — Moderate Problems5052462136
Usual Activities: Week 36 — Severe Problems79735
Usual Activities: Week 36 — Extreme Problems21201
Usual Activities: Week 52 — No Problems1831771217571
Usual Activities: Week 52 — Slight Problems151147876472
Usual Activities: Week 52 — Moderate Problems4041422219
Usual Activities: Week 52 — Severe Problems8126512
Usual Activities: Week 52 — Extreme Problems42110
Pain/Discomfort: Week 36 — No Problems9584554735
Pain/Discomfort: Week 36 — Slight Problems2062201279497
Pain/Discomfort: Week 36 — Moderate Problems8189793445
Pain/Discomfort: Week 36 — Severe Problems1311827
Pain/Discomfort: Week 36 — Extreme Problems01100
Pain/Discomfort: Week 52 — No Problems9088574544
Pain/Discomfort: Week 52 — Slight Problems2092101308093
Pain/Discomfort: Week 52 — Moderate Problems7772613831
Pain/Discomfort: Week 52 — Severe Problems109936
Pain/Discomfort: Week 52 — Extreme Problems00010
Anxiety/Depression: Week 36 — No Problems230259162115112
Anxiety/Depression: Week 36 — Slight Problems123113794451
Anxiety/Depression: Week 36 — Moderate Problems3727191816
Anxiety/Depression: Week 36 — Severe Problems45705
Anxiety/Depression: Week 36 — Extreme Problems11300
Anxiety/Depression: Week 52 — No Problems227254169111110
Anxiety/Depression: Week 52 — Slight Problems10686613841
Anxiety/Depression: Week 52 — Moderate Problems4834231719
Anxiety/Depression: Week 52 — Severe Problems55404
Anxiety/Depression: Week 52 — Extreme Problems00010
SecondaryEQ-5D Current Health VAS at Weeks 4, 12, and 24

EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
EQ-5D Current Health VAS at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 459 ± 20.559 ± 19.960 ± 20.456 ± 19.5
Week 1266 ± 20.366 ± 20.365 ± 19.659 ± 20.7
Week 2467 ± 23.169 ± 21.668 ± 22.264 ± 21.4
SecondaryEQ-5D Current Health VAS at Weeks 36, and 52

EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health.

Time frame:
Weeks 36, and 52
Reported as:
Mean · score on a scale
EQ-5D Current Health VAS at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3669 ± 22.772 ± 21.267 ± 24.373 ± 19.971 ± 21.1
Week 5272 ± 21.373 ± 21.071 ± 22.573 ± 20.670 ± 22.8
SecondaryChange From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24

The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · score on a scale
Change From Baseline in EQ-5D Current Health VAS at Weeks 4, 12, and 24
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline48 ± 22.549 ± 22.847 ± 21.846 ± 21.8
Change from Baseline at Week 411 ± 24.410 ± 25.213 ± 24.410 ± 25.1
Change from Baseline at Week 1218 ± 26.317 ± 27.417 ± 27.113 ± 26.5
Change from Baseline at Week 2419 ± 30.521 ± 28.921 ± 28.818 ± 29.3
Statistical analysis
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.049 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.0 · 95% CI 0.0 to 5.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.069 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 2.0 · 95% CI -0.0 to 5.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 7.0 · 95% CI 4.0 to 9.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = <0.001 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 6.0 · 95% CI 4.0 to 9.0
  • Filgotinib 200 mg vs Placebo · MMRM · p = 0.060 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 3.0 · 95% CI -0.0 to 6.0
  • Filgotinib 100 mg vs Placebo · MMRM · p = 0.003 (MMRM model included treatment, visit, treatment by visit, stratification factors, and baseline value as fixed effects, and participants being the random effect.) · Least squares mean difference: 5.0 · 95% CI 2.0 to 8.0
SecondaryChange From Baseline in EQ-5D Current Health VAS at Weeks 36, and 52

The EQ-5D-5L is a standardized measure of health status of the participant at the visit (same day) that provides a simple, generic measure of health for clinical and economic appraisal. Participant rates their current health state on a 0-100 VAS. It gets recorded on a vertical VAS in which the endpoints are labeled best imaginable health state is 100 (on the top) and worst imaginable health state is 0 (on the bottom). Higher scores of EQ VAS indicate better health. Positive change indicates improvement (better health).

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · score on a scale
Change From Baseline in EQ-5D Current Health VAS at Weeks 36, and 52
score on a scaleFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline48 ± 22.549 ± 22.847 ± 21.845 ± 21.647 ± 21.1
Change from Baseline at Week 3621 ± 30.623 ± 28.520 ± 30.928 ± 28.224 ± 26.0
Change from Baseline at Week 5225 ± 29.324 ± 28.524 ± 29.229 ± 28.623 ± 29.6
SecondaryWork Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of work time missed
Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA): Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
percentage of work time missedFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 48.5 ± 21.276.6 ± 16.479.2 ± 21.999.4 ± 21.41
Week 126.6 ± 17.065.4 ± 14.567.1 ± 18.469.5 ± 22.66
Week 244.4 ± 13.543.6 ± 10.247.2 ± 17.7210.5 ± 21.86
SecondaryWPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 36, and 52
Reported as:
Mean · percentage of work time missed
WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52
percentage of work time missedFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 365.5 ± 16.177.7 ± 19.467.0 ± 19.656.8 ± 19.798.4 ± 19.97
Week 524.8 ± 14.395.4 ± 15.107.4 ± 20.125.5 ± 13.245.8 ± 14.29
SecondaryWPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of impairment while working
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
percentage of impairment while workingFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 434.3 ± 22.6936.9 ± 24.0135.6 ± 22.3942.5 ± 23.54
Week 1226.3 ± 21.0726.9 ± 22.5727.6 ± 21.5134.0 ± 21.98
Week 2422.0 ± 21.2821.0 ± 20.7425.7 ± 21.9930.9 ± 23.11
SecondaryWPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 36, and 52
Reported as:
Mean · percentage of impairment while working
WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52
percentage of impairment while workingFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3620.2 ± 19.5419.6 ± 20.2721.2 ± 20.7421.5 ± 18.7225.8 ± 23.51
Week 5218.2 ± 18.8317.3 ± 19.2520.8 ± 21.7822.3 ± 21.8219.5 ± 20.04
SecondaryWPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of work productivity loss
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
percentage of work productivity lossFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 437.0 ± 24.6439.5 ± 25.1738.4 ± 24.5945.1 ± 25.18
Week 1229.5 ± 24.2529.3 ± 24.7330.7 ± 24.3436.7 ± 24.27
Week 2424.4 ± 23.0623.2 ± 22.6429.1 ± 23.8834.9 ± 26.04
SecondaryWPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 36, and 52
Reported as:
Mean · percentage of work productivity loss
WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52
percentage of work productivity lossFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3623.3 ± 22.0223.9 ± 23.9823.8 ± 22.9524.0 ± 21.3329.1 ± 26.79
Week 5220.6 ± 21.7420.5 ± 22.1524.3 ± 24.7725.7 ± 24.3222.3 ± 24.10
SecondaryWPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 4, 12, and 24
Reported as:
Mean · percentage of activity impairment
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
percentage of activity impairmentFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Week 444.6 ± 24.1846.2 ± 24.0546.4 ± 23.8452.1 ± 23.41
Week 1235.1 ± 23.8636.6 ± 24.5138.3 ± 25.5744.3 ± 23.73
Week 2430.2 ± 24.6930.4 ± 23.0732.5 ± 24.4039.3 ± 23.69
SecondaryWPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity.

Time frame:
Weeks 36, and 52
Reported as:
Mean · percentage of activity impairment
WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52
percentage of activity impairmentFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Week 3628.3 ± 23.3028.7 ± 23.4731.3 ± 25.4428.3 ± 22.4732.3 ± 23.62
Week 5226.0 ± 22.4426.3 ± 22.7128.1 ± 24.3828.6 ± 23.5728.9 ± 23.07
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of work time missed
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 4, 12, and 24
percentage of work time missedFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline12.0 ± 25.779.9 ± 20.9116.0 ± 27.5717.0 ± 29.52
Change from Baseline at Week 4-1.4 ± 21.24-2.1 ± 18.14-7.5 ± 24.26-5.7 ± 25.65
Change from Baseline at Week 12-4.3 ± 22.55-3.8 ± 18.37-7.5 ± 28.79-5.9 ± 27.94
Change from Baseline at Week 24-6.1 ± 24.77-3.8 ± 16.92-9.3 ± 28.99-1.5 ± 27.24
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Absenteeism (work time missed) due to RA: 100×{Q2/(Q2+Q4)}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · percentage of work time missed
Change From Baseline in WPAI-RA: Mean Percentage of Work Time Missed (Absenteeism) at Weeks 36, and 52
percentage of work time missedFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline12.0 ± 25.779.9 ± 20.9116.0 ± 27.5718.3 ± 31.6114.6 ± 26.88
Change from Baseline at Week 36-4.4 ± 24.04-1.5 ± 24.41-8.7 ± 27.43-6.2 ± 30.25-7.5 ± 25.00
Change from Baseline at Week 52-6.8 ± 26.27-1.7 ± 21.89-7.1 ± 24.00-7.4 ± 26.76-8.9 ± 27.90
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of impairment while working
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 4, 12, and 24
percentage of impairment while workingFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline49.1 ± 25.2348.0 ± 24.6150.8 ± 22.9852.5 ± 25.89
Change from Baseline at Week 4-15.1 ± 23.19-10.2 ± 22.82-15.3 ± 24.84-9.5 ± 23.68
Change from Baseline at Week 12-24.1 ± 25.83-21.9 ± 23.22-22.9 ± 24.88-17.1 ± 27.24
Change from Baseline at Week 24-27.4 ± 26.37-25.9 ± 26.59-23.3 ± 27.56-21.2 ± 29.33
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Presenteeism (impairment while working) due to RA: 100×{Q5/10}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · percentage of impairment while working
Change From Baseline in WPAI-RA: Mean Percentage of Impairment While Working Due to RA (Presenteeism) at Weeks 36, and 52
percentage of impairment while workingFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline49.1 ± 25.2348.0 ± 24.6150.8 ± 22.9853.8 ± 26.3553.6 ± 23.40
Change from Baseline at Week 36-29.7 ± 26.73-27.5 ± 26.28-27.8 ± 29.90-32.0 ± 26.82-26.4 ± 29.86
Change from Baseline at Week 52-31.7 ± 27.44-29.5 ± 24.66-29.4 ± 27.91-30.6 ± 28.24-32.5 ± 28.17
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of work productivity loss
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 4, 12, and 24
percentage of work productivity lossFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline51.3 ± 25.9550.6 ± 25.8754.3 ± 24.8555.8 ± 27.33
Change from Baseline at Week 4-14.6 ± 24.59-10.2 ± 23.71-16.8 ± 26.29-10.0 ± 24.06
Change from Baseline at Week 12-23.2 ± 28.18-22.3 ± 24.34-22.8 ± 26.61-17.5 ± 28.09
Change from Baseline at Week 24-27.1 ± 27.78-26.3 ± 27.29-23.6 ± 29.40-19.3 ± 30.81
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Work productivity loss (overall work impairment) due to RA: 100×{Q2/(Q2+Q4) + \[(1-Q2/(Q2+Q4) × (Q5/10)\]}. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · percentage of work productivity loss
Change From Baseline in WPAI-RA: Mean Percentage of Overall Work Productivity Impairment Due to RA at Weeks 36, and 52
percentage of work productivity lossFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline51.3 ± 25.9550.6 ± 25.8754.3 ± 24.8556.6 ± 27.3657.1 ± 25.14
Change from Baseline at Week 36-28.9 ± 27.16-25.7 ± 29.54-28.6 ± 31.48-31.7 ± 30.53-26.9 ± 31.02
Change from Baseline at Week 52-31.6 ± 29.17-28.4 ± 27.11-29.3 ± 29.38-30.3 ± 30.73-32.7 ± 29.65
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 4, 12, and 24
Reported as:
Mean · percentage of activity impairment
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 4, 12, and 24
percentage of activity impairmentFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo
Baseline61.5 ± 22.7460.5 ± 23.8561.3 ± 21.2062.2 ± 22.11
Change from Baseline at Week 4-17.0 ± 22.46-14.7 ± 22.07-14.8 ± 23.36-9.8 ± 20.98
Change from Baseline at Week 12-26.5 ± 25.17-24.1 ± 24.95-22.6 ± 24.93-16.9 ± 25.98
Change from Baseline at Week 24-30.7 ± 26.20-30.4 ± 25.45-28.6 ± 24.99-21.9 ± 27.78
SecondaryChange From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52

The WPAI is a questionnaire that measures impairments in work activities in participants with RA which consists of 6 questions: Q1-currently employed; Q2-work time missed due to RA; Q3-work time missed due to other reasons; Q4-hours actually worked; Q5-degree RA affected productivity while working (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant from working); Q6-degree RA affected productivity in regular unpaid activities (0-10 VAS, with 0 indicating no effect and 10 indicating RA completely prevented the participant's daily activities). Outcomes are expressed as impairment percentages: Activity impairment due to RA: 100×{Q6/10}. If Question 1 (Are you currently employed?) is 'NO', then only the activity impairment score can be determined. Higher numbers indicate greater impairment and less productivity. A negative change from baseline indicates improvement.

Time frame:
Baseline; Weeks 36, and 52
Reported as:
Mean · percentage of activity impairment
Change From Baseline in WPAI-RA: Mean Percentage of Activity Impairment Due to RA at Weeks 36, and 52
percentage of activity impairmentFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mg
Baseline61.5 ± 22.7460.5 ± 23.8561.3 ± 21.2062.9 ± 21.7459.7 ± 22.10
Change from Baseline at Week 36-32.6 ± 26.66-31.5 ± 25.66-30.2 ± 26.93-34.9 ± 26.60-27.5 ± 26.14
Change from Baseline at Week 52-34.8 ± 26.74-33.7 ± 26.44-32.9 ± 26.03-35.2 ± 28.00-30.8 ± 25.99

Adverse events

Collected over First dose date up to last dose date (Maximum: 54 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Filgotinib 200 mg3/475 (0.6%)35/475 (7.4%)128/475 (26.9%)
Filgotinib 100 mg1/480 (0.2%)40/480 (8.3%)142/480 (29.6%)
Adalimumab1/325 (0.3%)22/325 (6.8%)82/325 (25.2%)
Placebo to Filgotinib 200 mg1/190 (0.5%)7/190 (3.7%)36/190 (18.9%)
Placebo to Filgotinib 100 mg1/191 (0.5%)8/191 (4.2%)23/191 (12%)
Placebo2/475 (0.4%)21/475 (4.4%)61/475 (12.8%)
Most frequent serious events
Showing 10 of 126
Most frequent serious events
EventFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mgPlacebo
PneumoniaInfections and infestations4/4754/4803/3251/1900/1911/475
Chest painGeneral disorders0/4751/4800/3251/1900/1910/475
Road traffic accidentInjury, poisoning and procedural complications0/4750/4800/3251/1900/1910/475
ArthralgiaMusculoskeletal and connective tissue disorders0/4750/4800/3251/1900/1910/475
Ischaemic strokeNervous system disorders0/4750/4800/3251/1901/1910/475
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/4750/4800/3251/1900/1910/475
AngioedemaSkin and subcutaneous tissue disorders0/4750/4800/3251/1900/1910/475
DermatitisSkin and subcutaneous tissue disorders0/4750/4800/3251/1900/1910/475
Deep vein thrombosisVascular disorders0/4750/4801/3251/1900/1910/475
Meniere's diseaseEar and labyrinth disorders0/4750/4800/3250/1901/1910/475
Most frequent other events
Most frequent other events
EventFilgotinib 200 mgFilgotinib 100 mgAdalimumabPlacebo to Filgotinib 200 mgPlacebo to Filgotinib 100 mgPlacebo
Upper respiratory tract infectionInfections and infestations41/47549/48021/3258/1906/19114/475
NasopharyngitisInfections and infestations43/47548/48024/3257/1906/19125/475
Alanine aminotransferase increasedInvestigations17/47525/48021/3257/1903/19111/475
NauseaGastrointestinal disorders26/47516/4806/3254/1901/1917/475
Urinary tract infectionInfections and infestations18/47519/48017/32510/1908/1916/475
Aspartate aminotransferase increasedInvestigations12/47520/48017/3258/1903/1919/475

Baseline characteristics

The Safety Analysis Set included all participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Filgotinib 200 mgFilgotinib 100 mgAdalimumabPlaceboTotal
Mean52 ± 12.853 ± 12.653 ± 12.953 ± 12.853 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Filgotinib 200 mgFilgotinib 100 mgAdalimumabPlaceboTotal
Female3793992663911435
Male96815984320
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgAdalimumabPlaceboTotal
Race — American Indian or Alaska Native27272029103
Race — Asian: Japanese40412838147
Race — Asian: Chinese/Taiwanese/Hong Kong Chinese131281851
Race — Asian: Korean13104734
Race — Asian: Other56522546179
Race — Black or African American67101235
Race — Native Hawaiian or Pacific Islander10023
Race — White3123242293191184
Race — Other761317
Race — Not Permitted01012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Filgotinib 200 mgFilgotinib 100 mgAdalimumabPlaceboTotal
Ethnicity — Hispanic or Latino67715470262
Ethnicity — Not Hispanic or Latino4043992684001471
Ethnicity — Not Permitted4103522
Region of Enrollment
Region of Enrollment(Participants)Filgotinib 200 mgFilgotinib 100 mgAdalimumabPlaceboTotal
United States47553760199
South Africa12113834
South Korea12104733
Spain1436730
Germany565420
New Zealand553518
United Kingdom124613
Canada443112
Israel412411
Belgium234110
Italy21216
Netherlands01012
Australia01001
Ireland01001
Poland78826474298
Ukraine66734155235
India40391939137
Russia34322230118
Hungary121251746
Bulgaria7761434
Czechia7771334
Romania12621131
Serbia178521
Slovakia22138
Mexico33332534125
Argentina1517101557
Taiwan12971644
Thailand766423
Hong Kong13127
Japan40412838147
08

Study locations

237 sites
  • Huntsville, Alabama, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Covina, California, United States
  • Hemet, California, United States
  • La Jolla, California, United States
  • Palm Desert, California, United States
  • Upland, California, United States
  • Victorville, California, United States
  • Whittier, California, United States
  • Clearwater, Florida, United States
  • DeBary, Florida, United States
  • Jacksonville, Florida, United States
  • Miami Lakes, Florida, United States
  • Miami, Florida, United States
  • New Port Richey, Florida, United States
  • Orlando, Florida, United States
  • Plantation, Florida, United States
  • Kansas City, Kansas, United States
  • Wichita, Kansas, United States
  • Elizabethtown, Kentucky, United States
  • Lexington, Kentucky, United States
  • Cumberland, Maryland, United States
  • Hagerstown, Maryland, United States
  • Wheaton, Maryland, United States
  • Detroit, Michigan, United States
  • Saint Clair Shores, Michigan, United States
  • Eagan, Minnesota, United States
  • Hattiesburg, Mississippi, United States
  • Tupelo, Mississippi, United States
  • Saint Louis, Missouri, United States
  • Toms River, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Salisbury, North Carolina, United States
  • Bethlehem, Pennsylvania, United States
  • Duncansville, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Wyomissing, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Columbia, South Carolina, United States
  • Orangeburg, South Carolina, United States
  • Memphis, Tennessee, United States
  • Beaumont, Texas, United States
  • Corpus Christi, Texas, United States
  • Dallas, Texas, United States
  • Mesquite, Texas, United States
  • San Antonio, Texas, United States
  • Webster, Texas, United States
  • Buenos Aires, Argentina
  • Caba, Argentina
  • Mendoza, Argentina
  • Quilmes, Argentina
  • San Fernando, Argentina
  • San Juan, Argentina
  • San Miguel De Tucumán, Argentina
  • Victoria Park, Western Australia, Australia
  • Brussels, Belgium
  • Genk, Belgium
  • Merksem, Belgium
  • Dobrich, Bulgaria
  • Haskovo, Bulgaria
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Vidin, Bulgaria
  • Trois-Rivieres, Quebec, Canada
  • Praha 4, Praha, Czechia
  • Brno, Czechia
  • Ostrava-Poruba, Czechia
  • Ostrava, Czechia
  • Prague 10, Czechia
  • Praha 4, Czechia
  • Uherske Hradiste, Czechia
  • Frankfurt a Main, Germany
  • Hamburg, Germany
  • Ratingen, Germany
  • Hong Kong, Hong Kong
  • Kalocsa, Bacs-kiskun, Hungary
  • Szentes, Csongrad, Hungary
  • Székesfehérvár, Fejer, Hungary
  • Budapest, Hungary
  • Eger, Hungary
  • Ahmedabad, India
  • Bangalore, India
  • Chennai, India
  • Delhi, India
  • Gurgaon, India
  • Hyderabad, India
  • Jaipur, India
  • Kolkata, India
  • Lucknow, India
  • Mangalore, India
  • Nagpur, India
  • New Delhi, India
  • Pune, India
  • Secunderabad, India
  • Srikakulam, India
  • Surat, India
  • Vadodara, India
  • Visakhapatnam, India

Showing the first 100 of 237 sites across 30 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Combe B, Kivitz A, Tanaka Y, van der Heijde D, Matzkies F, Bartok B, et al. Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH 1 primary outcome results. Ann Rheum Dis 2019; 78 (supplement 2):A77.
  • Tanaka Y, Atsumi T, Aletaha D, Bartok B, Pechonkina A, Han L, Emoto K, Kano S, Rajendran V, Takeuchi T. Benefit of Filgotinib, a JAK1 Preferential Inhibitor, in Rheumatoid Arthritis Patients with Previous Rapid Radiographic Progression: Post Hoc Analysis of Two Trials. Rheumatol Ther. 2023 Feb;10(1):161-185. doi: 10.1007/s40744-022-00503-3. Epub 2022 Nov 3. PubMed 36327094 ↗
  • Combe B, Besuyen R, Gomez-Centeno A, Matsubara T, Sancho Jimenez JJ, Yin Z, Buch MH. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis. Rheumatol Ther. 2023 Feb;10(1):35-51. doi: 10.1007/s40744-022-00494-1. Epub 2022 Oct 7. PubMed 36205910 ↗
  • Bingham CO 3rd, Walker D, Nash P, Lee SJ, Ye L, Hu H, Khalid JM, Combe B. The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies. Arthritis Res Ther. 2022 Jan 3;24(1):11. doi: 10.1186/s13075-021-02677-7. PubMed 34980223 ↗
  • Combe B, Kivitz A, Tanaka Y, van der Heijde D, Simon JA, Baraf HSB, Kumar U, Matzkies F, Bartok B, Ye L, Guo Y, Tasset C, Sundy JS, Jahreis A, Genovese MC, Mozaffarian N, Landewe RBM, Bae SC, Keystone EC, Nash P. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial. Ann Rheum Dis. 2021 Jul;80(7):848-858. doi: 10.1136/annrheumdis-2020-219214. Epub 2021 Jan 27. PubMed 33504485 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Jul 2018, 22 months.

Results were first posted in Jan 2021, 2 years 6 months after primary completion. A results delay was requested in Jun 2019.

Of 116 industry-sponsored phase 3 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 31. This study's 22 months is close to that.

Counting every sponsor, half of 148 studies reached it within 26 months; a quarter within 17 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2016
First posted
Sep 7, 2016
StartActual
Aug 30, 2016
Primary completionActual
Jul 4, 2018
CompletionActual
Jun 20, 2019
Results delay requested
Jun 28, 2019
Results first posted
Jan 19, 2021
Last update
Jun 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02889796
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Sep 7, 2016
Start date
Aug 30, 2016
Primary completion
Jul 4, 2018
Completion
Jun 20, 2019
Results posted
Jan 19, 2021
Last update
Jun 9, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion